rxpertusa logo spacer rxpertusa wings
logo spacer spacer spacer
spacer home
about us
assessment tools
sample consult
acps services
contact us
favorite links

red line

spacer spacer news

The latest Mainline newsletters for the General Public are listed here.


For healthcare professionals we have a Mainline newsletter in a Professional version here.


What will 1 out of every three seniors experience this year? A Fall! Why?

Printer Friendly


Volume 3 April 10, 2007 Number 16

An Exclusive Continuing Education Publication of Acadiana Consultant Pharmacy Service
Author, Publisher, Editor-in Chief, Typesetter & Printer, Charles S. Feucht,PD,FASCP PharmD candidate

Medication News & Update

FDA staff stated that it reviewed 202 cases of CNS adverse events associated with oxybutynin, including 37 paediatric cases and 143 involving adults. The review showed that 27 percent of paediatric cases mentioned hallucinations, and 25 percent of cases in patients 60 years or older involved hallucinations. In patients aged 17 to 59 years, 11 percent of adverse event reports included hallucinations.

In its recommendations, the agency staff suggested that the drug's labelling state that "oxybutynin has the potential to cause anticholinergic CNS effects" and that among these types of adverse events reported, "hallucinations and agitation [were] prominent among paediatric cases, and confusion, hallucinations, and sedation prominent among reports involving geriatric use."



Home ] [ About Us  ] [ Assessment Tools  ] [ Sample Consult  ]
Contact Us  ] [ Favorite Links  ]

Copyright © www.rxpertusa.com. Designed by PcHousekeeping.com
  spacer spacer